|Chemical and physical data|
|Molar mass||571.55 g·mol−1|
|3D model (JSmol)|
Baloxavir marboxil (trade name Xofluza) is an antiviral medication for treatment of influenza A and influenza B FDA-approved in October 2018 and given as a single dose by mouth. It may reduce the duration of flu symptoms by about a day. It was developed by Shionogi Co., a Japanese pharmaceutical company, and Roche AG.
Baloxavir marboxil is an influenza therapeutic agent (cap-dependent endonuclease inhibitor), characterized by taking a single dose by mouth. Baloxavir marboxil may prevent influenza replication by inhibiting the cap-dependent endonuclease activity of the viral polymerase. This is unlike neuraminidase inhibitors such as oseltamivir (Tamiflu) and zanamivir (Relenza) that inhibit the action of neuraminidase, which liberates viruses from the infected cells surface. It achieves this by inhibiting the process known as cap snatching, which is a mechanism exploited by viruses to hijack the host mRNA transcription system to allow synthesis of viral RNAs.
Common side effects are diarrhea and bronchitis.
Baloxavir marboxil was approved for sale in Japan in February 2018. On October 24, 2018 the U.S. FDA approved baloxavir marboxil for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours.
- "Flu drug, taken in single dose, could upend treatment if approved in U.S." STAT. 27 June 2018.
- Dias, Alexandre; Bouvier, Denis; Crépin, Thibaut; McCarthy, Andrew A.; Hart, Darren J.; Baudin, Florence; Cusack, Stephen; Ruigrok, Rob W. H. (2009). "The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit". Nature. 458 (7240): 914–918. doi:10.1038/nature07745. ISSN 0028-0836.
- "FDA approves new drug to treat influenza". 24 October 2018 – via www.fda.gov.
- "XOFLUZA (Baloxavir Marboxil) Tablets 10mg/20mg Approved For The Treatment Of Influenza Types A And B In Japan". 23 February 2018 – via www.publicnow.com.